Business
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
SOUTH SAN FRANCISCO, Calif. and ELK GROVE VILLAGE, Ill., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA today
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. and ELK GROVE VILLAGE, Ill., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA). Cytokinetics will be a National Gold Sponsor in support of several key Cure SMA initiatives across the United States. In September, Cytokinetics will participate as a sponsor of a long-time Bay Area event, the Northern California Walk-n-Roll, with the goal of increasing awareness and fundraising for SMA. In December, Cytokinetics will participate as a sponsor of the 10th Annual Hope on the Hill Congressional Dinner, which brings together individuals with SMA, their families, government officials and industry leaders to advocate for awareness and celebrate the milestones achieved in SMA research. “We continue to recognize the needs of those with SMA and are proud of our longstanding commitment to support the priorities of Cure SMA,” said Robert I. Blum, President and Chief Executive Officer of Cytokinetics. “Through our shared objectives, this partnership reflects one of the many ways Cytokinetics works to amplify patient voice through collaborative community engagement.” “Cytokinetics’ continued support of Cure SMA has been immensely valuable, especially over the last 18 months as we advanced our goals and activities in a new, virtual setting,” said Kenneth Hobby, President of Cure SMA. “Among the SMA community, there remains a large gap in access to care and support, and we appreciate our collaborative partnership with Cytokinetics to help facilitate various initiatives aimed at promoting awareness of appropriate care in the broader community, which will help improve and expand access.” About SMA Spinal muscular atrophy (SMA) is a severe, genetic neuromuscular disease that leads to debilitating muscle function and progressive, often fatal, muscle weakness. It occurs in 1 in 11,000 live births each year and is one of the most common potentially fatal genetic disorders. Spinal muscular atrophy manifests in various degrees of severity as progressive muscle weakness resulting in respiratory and mobility impairment. There are four types of SMA, named for age of initial onset of muscle weakness and related symptoms: Type 1 (Infantile), Type 2 (I...